<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200408046990N14</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-10-06</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of chamomile oral solution on neurological complications caused by chemotherapy regimens containing paclitaxel in cancer patients.</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the protective effect of chamomile oral solution on the incidence of neurotoxicity caused by chemotherapy regimens containing paclitaxel in cancer patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/72529</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Randomization will be done based on the table of random numbers prepared from randomization.com. In this study, the allocation of people to two groups will be done using the 4 permutation block method. In this method, A represents the person who receives the intervention and B represents the person who is placed in the control group. The letter A or B will be assigned to the drug or placebo by a person not involved in entering the patients, evaluating the patients, and analyzing the data, and will not be decoded until the end of the analysis. Considering the quadruple block; We give code 0 to AABB permutation, code 1 to ABAB permutation, code 2 to ABBA, code 3 to BAAB, code 4 to BBAA and code 5 to BABA.Then, using the table of random numbers, we randomly select a starting point and then consider 5 numbers in a row or column. Considering the order of the numbers in the table, we place the permutation corresponding to each number we come across, for example, if the first three numbers of the table of random numbers are 1, 0, and 5 respectively, the order of receiving treatment by the first 12 people in two groups, respectively From left to right it will be ABABAABBBABA. In this process of generating random numbers, we skip the numbers 6 to 9 to select blocks of four.
Randomization type: 1- Simple
2- Blocked block
3- Stratified, Blinding description: In this study, the drug packages prepared in the two intervention and control groups are the same, and the form of the oral formulation of the drug and the placebo are also similar to each other, and both are prepared by the same pharmaceutical company with a similar appearance and are provided to the plan administrators.</study_design>
      <phase>3</phase>
      <hc_freetext>Various cancers treated by paclitaxel.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In the drug group, starting one day before the paclitaxel injection, three times a day each time in the amount of 5 cc of the oral solution containing the hydroalcoholic extract of chamomile (each 5 cc contains 500 mg of dry extract) every two or three weeks for 4 courses for It will be a maximum of 12 weeks. Intervention 2: Control group: In the placebo group, a placebo  is consumed three times a day, 5 cc each time. The dosage of paclitaxel will be 175 mg/m2 every two or three weeks for 4 courses for a maximum of 12 weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The findings will be published in an article. Study protocol and statistical analysis will be used for article publication.

When:
One year after the end of the study it will be published and available in databases.

To whom:
If the funding sponsor allowed, the findings will be available for researchers, clinicians, and scientific centers.

Conditions:
The other researchers can use our findings in their review articles and meta analysis.

Where to obtain:
For this purpose, you can contact with Sepideh Elyasi, at Clinical Pharmacy Department, School of Pharmacy, Vakil Abad Aven., Mashhad, Iran. Email: elyasis@mums.ac.ir

How to obtain:
After receiving the query, dependent on the requested data, the scientific responsible person of the study will response to the query in coordinate with the sponsor within 2 weeks

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sepideh Elyasi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Pharmacy; Ferdowsi University; Vakilabad Boulevard</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>17871 91886</zip>
        <telephone>+98 51 3180 1588</telephone>
        <email>elyasis@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sepideh Elyasi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Pharmacy; Ferdowsi University; VakilAbad Boulevard</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>17871 91886</zip>
        <telephone>+98 51 3180 1588</telephone>
        <email>elyasis@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Suffering from cancer and starting chemotherapy regimen containing paclitaxel at a dose of 175 mg/m2.
age between 18-70 yers</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Liver failure (due to the change in drug clearance): If the ALT and AST tests are more than two to three times the normal level at the beginning of the treatment, the patient will be excluded from the study.
Renal failure (GFR&lt;30 ml/min)
Neuropathy at baseline
Having diabetes or other disorders that cause neuropathy
Taking supplements containing antioxidant compounds
Use of neuromodulator drugs such as compounds containing calcium or magnesium and anticonvulsant drugs such as gabapentin and antidepressants from tricyclic antidepressants and serotonin-norepinephrine reuptake inhibitors.
Taking warfarin
alcohol consumption
Smoking
Lack of patient satisfaction
Having a history of allergy to chamomile
BMI&gt;30
Use of other neurotoxic drugs in the chemotherapy regimen, such as platinums or vincristine
Suffering from concurrent neuromuscular diseases such as myasthenia gravis
Guillain Barre syndrome, multifocal motor neuropathy and chronic inflammatory demyelinating polyneuropathy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>C00-C97</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>malignant neoplasms</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In the drug group, starting one day before the paclitaxel injection, three times a day each time in the amount of 5 cc of the oral solution containing the hydroalcoholic extract of chamomile (each 5 cc contains 500 mg of dry extract) every two or three weeks for 4 courses for It will be a maximum of 12 weeks.</i_keyword>
      <i_keyword>Control group: In the placebo group, a placebo  is consumed three times a day, 5 cc each time. The dosage of paclitaxel will be 175 mg/m2 every two or three weeks for 4 courses for a maximum of 12 weeks.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Neuropathy. Timepoint: at baseline-after each course-at the end of study. Method of measurement: based on NCI-CTC (national cancer institute-common toxicity criteria version 5).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Sleep assessment. Timepoint: at the beginning of study-at the end of study. Method of measurement: Based on the Pittsburgh Sleep Quality Index.</sec_outcome>
      <sec_outcome>Assessment of anxiety. Timepoint: at the beginning of study-at the end of study. Method of measurement: Generalized Anxiety Disorder scale questionnaire index.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-08-28</approval_date>
        <contact_name>Ethics committee of Mashhad University of Medical Sciences</contact_name>
        <contact_address>Qureshi Building, Daneshgah street Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
